Abraxane Plus Gemcitabine Improves Survival in Phase III Study of Patients With Advanced Pancreatic Cancer

January 23, 2013
Australian biopharmaceutical company Specialized Therapeutics Australia announced a Phase III clinical trial of world leading breast cancer drug abraxane (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving two years.
PR Newswire